Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2014

View Archived Issues

Academic team divulges novel FimH inhibitors

VolitionRx enters into agreement with University of Oxford for endometriosis diagnostic

Radboud University Medical Center wins NuGEN award for sarcoma genomics research

Medgenics and CHOP collaborate on pediatric rare and orphan genetic diseases

Enterome and AbbVie establish microbiome collaboration in Crohn's disease

Glionova Therapeutics raises financing for clinical development of glioblastoma candidate

BioCardia to conduct phase III trial of autologous bone marrow cell therapy for heart failure

GenomeDx and Mayo Clinic collaborate on expanded use of prostate cancer test

FDA approves supplemental NDAs for Invega Sustenna

First-in-human results for GSK-2878175 in healthy volunteers and patients with HCV

Advaxis submits IND for phase I/II study of ADXS-HPV and MEDI-4736 for HPV-related cancers

Phase II study of masitinib in hepatocellular cancer recommended to continue by DSMB

Safety and pharmacokinetic results for first-in-class HBV core inhibitor NVR-3-778

Suppression of Bcl-xL in hepatocellular carcinoma cells by TPU-0014

Presage expands cancer research agreement with Takeda

Arrien Pharmaceuticals patent details novel dual ITK/JAK3 inhibitors

Innocrin Pharmaceuticals to participate in phase II trial of VT-464 in prostate cancer

New lead candidates for broad-spectrum antimalarial drugs presented

University of Queensland developing new vaccine technology for polio

Japanese researchers describes anti-NLRR-1 MAbs

Merck & Co. presents preliminary phase I results for recombinant dengue vaccine

Janssen licenses Geron's imetelstat

Quatsomes EGF formulation developed to treat diabetic foot ulcers

Clinical trials of favipiravir and brincidofovir planned in Ebola virus outbreak region

Mitsubishi Tanabe seeks Japanese approval of Radicut for ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...